EG24361A - 4-pyrimiding1-n-acy1.l.phenlalanines - Google Patents

4-pyrimiding1-n-acy1.l.phenlalanines

Info

Publication number
EG24361A
EG24361A EG20001502A EG20001502A EG24361A EG 24361 A EG24361 A EG 24361A EG 20001502 A EG20001502 A EG 20001502A EG 20001502 A EG20001502 A EG 20001502A EG 24361 A EG24361 A EG 24361A
Authority
EG
Egypt
Prior art keywords
phenlalanines
acy1
Prior art date
Application number
EG20001502A
Other languages
English (en)
Inventor
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG24361A publication Critical patent/EG24361A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EG20001502A 1999-12-06 2000-12-03 4-pyrimiding1-n-acy1.l.phenlalanines EG24361A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
EG24361A true EG24361A (en) 2009-03-04

Family

ID=22614222

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001502A EG24361A (en) 1999-12-06 2000-12-03 4-pyrimiding1-n-acy1.l.phenlalanines

Country Status (35)

Country Link
EP (1) EP1237878B1 (sr)
JP (1) JP3824935B2 (sr)
KR (1) KR100522344B1 (sr)
CN (1) CN1218943C (sr)
AR (1) AR034401A1 (sr)
AT (1) ATE357433T1 (sr)
AU (1) AU783348B2 (sr)
BR (1) BR0016195A (sr)
CA (1) CA2392570C (sr)
CO (1) CO5080772A1 (sr)
CY (1) CY1106626T1 (sr)
CZ (1) CZ303435B6 (sr)
DE (1) DE60034061T2 (sr)
DK (1) DK1237878T3 (sr)
EG (1) EG24361A (sr)
ES (1) ES2282162T3 (sr)
HK (1) HK1054384B (sr)
HR (1) HRP20020468B1 (sr)
HU (1) HU229105B1 (sr)
IL (2) IL149617A0 (sr)
JO (1) JO2283B1 (sr)
MA (1) MA26850A1 (sr)
MX (1) MXPA02005564A (sr)
MY (1) MY126972A (sr)
NO (1) NO322866B1 (sr)
NZ (1) NZ518828A (sr)
PE (1) PE20010961A1 (sr)
PL (1) PL207160B1 (sr)
PT (1) PT1237878E (sr)
RS (1) RS50371B (sr)
RU (1) RU2266901C2 (sr)
SI (1) SI1237878T1 (sr)
TW (1) TWI256387B (sr)
WO (1) WO2001042225A2 (sr)
ZA (1) ZA200203533B (sr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PL223152B1 (pl) * 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
WO2003053926A1 (fr) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Nouveau derive de phenylalanine
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
BRPI0514415A (pt) * 2004-08-16 2008-06-10 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
JP2009516729A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−フェニルアラニン誘導体
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
EP1984330A1 (en) * 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
EP2039687B1 (en) 2006-06-19 2012-05-02 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
PE20090705A1 (es) 2007-09-17 2009-07-17 Abbott Lab Derivados de uracilo en el tratamiento de hepatitis c
DK2368882T3 (en) 2007-09-17 2014-12-01 Abbvie Bahamas Ltd Anti-infective pyrimidines and uses thereof.
ATE512954T1 (de) 2007-09-17 2011-07-15 Abbott Lab Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
WO2010075276A1 (en) * 2008-12-22 2010-07-01 Icl-Ip America Inc. Water miscible solvent based process for purifying a bisphosphate
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
KR101893751B1 (ko) 2010-07-16 2018-09-03 애브비 아일랜드 언리미티드 컴퍼니 항바이러스성 화합물의 제조 방법
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2854254A1 (en) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA2928619C (en) 2013-10-29 2019-04-02 Ajinomoto Co., Inc. Sulfonamide derivative and pharmaceutical use thereof
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017382B1 (en) * 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
DE69821950T2 (de) * 1997-08-22 2004-12-16 F. Hoffmann-La Roche Ag N-aroylphenylalaninderivate
PL193283B1 (pl) * 1997-08-22 2007-01-31 Hoffmann La Roche Nowe pochodne N-aroilofenyloalaniny, ich zastosowanie i środek leczniczy
AR035838A1 (es) * 1999-01-22 2004-07-21 Elan Pharm Inc Compuestos multiciclicos que inhiben la adhesion de leucocitos mediada por vla-4 y el uso de los mismos para la preparacion de un medicamento

Also Published As

Publication number Publication date
PT1237878E (pt) 2007-06-18
ZA200203533B (en) 2003-08-04
CZ20022351A3 (cs) 2003-04-16
HK1054384B (zh) 2005-12-09
CY1106626T1 (el) 2012-01-25
HUP0204081A3 (en) 2003-07-28
BR0016195A (pt) 2002-08-13
DE60034061T2 (de) 2007-12-13
AU783348B2 (en) 2005-10-20
YU40402A (sh) 2005-03-15
PL207160B1 (pl) 2010-11-30
IL149617A (en) 2007-10-31
CO5080772A1 (es) 2001-09-25
NZ518828A (en) 2004-03-26
CA2392570C (en) 2010-05-11
RU2002117422A (ru) 2004-03-10
NO20022633L (no) 2002-06-04
RU2266901C2 (ru) 2005-12-27
EP1237878A2 (en) 2002-09-11
WO2001042225A3 (en) 2002-02-21
RS50371B (sr) 2009-11-10
CA2392570A1 (en) 2001-06-14
CN1218943C (zh) 2005-09-14
ES2282162T3 (es) 2007-10-16
HRP20020468B1 (en) 2009-02-28
AU2669601A (en) 2001-06-18
JO2283B1 (en) 2005-09-12
HRP20020468A2 (en) 2004-04-30
NO20022633D0 (no) 2002-06-04
AR034401A1 (es) 2004-02-25
PL357601A1 (en) 2004-07-26
JP3824935B2 (ja) 2006-09-20
CZ303435B6 (cs) 2012-09-12
PE20010961A1 (es) 2001-09-26
MY126972A (en) 2006-11-30
HUP0204081A2 (en) 2003-05-28
MA26850A1 (fr) 2004-12-20
WO2001042225A2 (en) 2001-06-14
EP1237878B1 (en) 2007-03-21
JP2003516396A (ja) 2003-05-13
SI1237878T1 (sl) 2007-08-31
WO2001042225A8 (en) 2002-06-06
KR100522344B1 (ko) 2005-10-20
KR20020063906A (ko) 2002-08-05
TWI256387B (en) 2006-06-11
MXPA02005564A (es) 2002-09-02
HU229105B1 (en) 2013-07-29
IL149617A0 (en) 2002-11-10
HK1054384A1 (en) 2003-11-28
DE60034061D1 (de) 2007-05-03
NO322866B1 (no) 2006-12-18
DK1237878T3 (da) 2007-07-30
CN1407972A (zh) 2003-04-02
ATE357433T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200200477B (en) 2-pyrazolin-5-ones.
HK1052037A1 (en) Structural member.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
ZA200202537B (en) Pour-on-formulations.
ZA200201829B (en) New phenylpiperazines.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1029502A1 (en) Slider-pull-assembling unit.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
MXPA02000261A (es) Aminoindanos novedosos.
ZA200108481B (en) 8A- and 9A-15-membered lactams.
GB0029720D0 (en) I.S machine7544232001
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200204581B (en) Nitro-sulfobenzamides.
HK1031254A1 (en) Tachogragh.
MXPA01013157A (es) Perfil.
ZA200005361B (en) Positioning arrangement.
ZA200001527B (en) De-sleeving.
ZA200203458B (en) Diaryl-enynes.
ZA200007821B (en) Hidroponiese Plantproduksiestelsel.
ZA200007026B (en) Acart.